PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31896113-12 2020 The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice. Sirolimus 109-118 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 83-88 31878201-5 2019 In this study we demonstrated that rapamycin, at a clinically tolerable concentration (10 nM), inhibited the phosphorylation of S6, but not the critical eIF4E releasing Thr 37/46 phosphorylation sites of 4E-BP1 in TSC2-deficient LAM-derived cells. Sirolimus 35-44 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 204-210 30552925-0 2019 Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin. Sirolimus 82-91 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 63-69 31487224-7 2019 The reduction of protein synthesis was associated with a marked inhibition of mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1, a mechanism consistent with reduced translation initiation. Sirolimus 98-107 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 156-217 30552925-2 2019 Based on the well-described effects of mTORC1/rapamycin complex on 4E-BP1 phosphorylation/s, it is generally accepted that rapamycin is a global inhibitor of cap-dependent translation. Sirolimus 46-55 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 67-73 30552925-3 2019 We have previously shown that 4E-BP1 resistance to rapamycin was overcome by the stoichiometric abundance of S6K1. Sirolimus 51-60 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 30-36 30552925-4 2019 Now we present evidence that the TOS-bearing amino terminal domain of S6K1 is sufficient to relieve the rapamycin resistance of 4E-BP1 as TOS deleted variants of S6K1, active or inactive with regard to S6K1 activity failed to bring about relief of 4E-BP1 resistance to rapamycin. Sirolimus 104-113 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 128-134 30552925-6 2019 The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently. Sirolimus 110-119 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 135-141 28969943-8 2018 Moreover, 4E-BP1, a target of mTOR, appeared to mediate the protective effects of rapamycin. Sirolimus 82-91 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 10-16 30050079-8 2018 In combination with tamoxifen (inhibiting ESR1), both S6RP phosphorylation and rapamycin-induced 4E-BP1 upregulation in TNBC bulk cells was inhibited. Sirolimus 79-88 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 97-103 30602778-3 2019 Here we demonstrate that rapamycin-insensitive mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-beta1 stimulated collagen synthesis in human lung fibroblasts, whereas canonical PI3K/Akt signaling is not required. Sirolimus 25-34 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 68-74 28696243-8 2018 RapaLink-1, a TORKi linked to rapamycin, represents a drug with improved pharmacology against 4EBP1. Sirolimus 30-39 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 94-99 27832967-9 2017 Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent of ATP concentration and that it is a selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 activity. Sirolimus 44-53 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 165-170 28300280-3 2018 Here, we show that the inhibitory effect of rapamycin on hsBAFF-promoted B cell proliferation/survival is also related to blocking hsBAFF-stimulated phosphorylation of Akt, S6K1, and 4E-BP1, as well as expression of survivin in normal and B-lymphoid (Raji and Daudi) cells. Sirolimus 44-53 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 183-189 27832967-9 2017 Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent of ATP concentration and that it is a selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 activity. Sirolimus 44-53 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 217-222 27297394-4 2016 Utilizing Western blot analysis, we demonstrate that similar to rapamycin (a known mTOR inhibitor), mf downregulate the phosphorylation of mTOR and its regulatory proteins, p70S6K1 and 4E-BP1, a process essential for DC protein synthesis. Sirolimus 64-73 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 173-191 27245614-5 2016 Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin. Sirolimus 13-22 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 147-153 26189041-1 2015 BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Sirolimus 47-56 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 173-179 26002629-8 2015 Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect. Sirolimus 182-191 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 93-99 26189041-2 2015 Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistance in 4E-BP1 null lymphoma cells. Sirolimus 38-47 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 108-114 26540919-7 2015 The expression levels of P-mTOR, P-70S6, P-4EBP1 in spherical cells were gradually decreased with increasing of the concentrations of rapamycin, but the difference of the expression levels of mTOR, P70S6, 4EBP1 were not significant. Sirolimus 134-143 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 43-48 26540919-7 2015 The expression levels of P-mTOR, P-70S6, P-4EBP1 in spherical cells were gradually decreased with increasing of the concentrations of rapamycin, but the difference of the expression levels of mTOR, P70S6, 4EBP1 were not significant. Sirolimus 134-143 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 205-210 25657110-7 2015 Furthermore, rapamycin, a specific inhibitor of mTOR, almost completely blocked FN-induced phosphorylation of 4E-BP1 and also partially abrogated the stimulatory effects of FN on GBC cell proliferation and invasion. Sirolimus 13-22 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 110-116 25988388-5 2015 The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1. Sirolimus 42-51 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 167-195 25961827-0 2015 AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Sirolimus 25-34 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 103-109 25961827-2 2015 Here, we found that activated AKT signaling is associated with rapamycin resistance in breast and colon cancers by sustained phosphorylation of the translational repressor 4E-BP1. Sirolimus 63-72 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 172-178 25961827-3 2015 Treatment of tumor cells with rapamycin or the AKT inhibitor MK2206 showed a limited activity in inhibiting 4E-BP1 phosphorylation, cap-dependent translation, cell growth and motility. Sirolimus 30-39 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 108-114 25659819-4 2015 Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 188-194 25659819-4 2015 Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation. Sirolimus 135-144 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 188-194 25659819-5 2015 Micro-molar doses of rapamycin are required for complete G1 cell cycle arrest - indicating that 4E-BP1 is a critical target of mTOR for promoting cell cycle progression. Sirolimus 21-30 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 96-102 24682932-8 2014 Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P < 0.05). Sirolimus 170-179 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 98-104 25880415-16 2015 Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 47-53 25439783-7 2015 TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E. Sirolimus 28-37 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 161-167 25439783-8 2015 These data suggest that the 4E-BP1/eIF4E ratio is a determinant for the response of TE1 and TE2 cells to rapamycin treatment. Sirolimus 105-114 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 28-34 25439783-9 2015 Egr-1 expression was higher in TE2 cells compared with other esophageal cancer cell lines, and its knockdown increased 4E-BP1 expression in TE2 cells, which became sensitive to rapamycin treatment. Sirolimus 177-186 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 119-125 25439783-12 2015 Thus, the 4E-BP1/eIF4E ratio may represent a therapeutic index for the prediction of clinical outcome of rapamycin treatment in patients with esophageal squamous cell carcinoma. Sirolimus 105-114 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 10-16 25762619-6 2015 Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion. Sirolimus 61-70 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 191-197 25762619-6 2015 Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion. Sirolimus 61-70 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 318-324 25762619-6 2015 Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion. Sirolimus 61-70 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 326-334 25744729-8 2015 Moreover, we also found rapamycin significantly decreased phosphorylated p70S6K1 and phosphorylated 4EBP1 in both samples. Sirolimus 24-33 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 100-105 25200808-9 2015 The association of bacillus Calmette-Guerin with rapamycin but not rapamycin monotherapy affected p70S6K1 and 4E-BP1 phosphorylation with no features of in situ carcinoma (pTis). Sirolimus 49-58 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 98-116 25439783-6 2015 RESULTS: The 4E-BP1/eIF4E ratio was adjusted to evaluate the response to rapamycin treatment in TE1 and TE2 esophageal cancer cells. Sirolimus 73-82 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 13-19 25439783-7 2015 TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E. Sirolimus 28-37 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 72-78 24682932-9 2014 In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K. Sirolimus 15-24 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 132-138 24675464-5 2014 However, 3 days following ligation with rapamycin treatment, a selective mTOR inhibitor, gland weights were maintained, 4E-BP1 and S6rp phosphorylation was inhibited, and there were morphological signs of recovery from atrophy. Sirolimus 40-49 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 120-126 23708663-0 2014 Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. Sirolimus 65-74 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 33-37 23376634-3 2013 This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E. Sirolimus 58-67 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 105-111 23376634-3 2013 This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E. Sirolimus 58-67 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 146-152 23482748-7 2013 Rapamycin induced eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) hyperphosphorylation in three cell lines. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 69-75 24358826-1 2012 The recent development of mammalian target of rapamycin (mTOR) kinase domain inhibitors and genetic dissection of rapamycin-sensitive and -insensitive mTOR protein complexes (mTORC1 and mTORC2) have revealed that phosphorylation of the mTOR substrate 4E-BP1 on amino acids Thr37 and/or Thr46 represents a rapamycin-insensitive activity of mTORC1. Sirolimus 46-55 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 251-257 23261705-4 2013 Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6. Sirolimus 42-51 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 101-109 23273915-7 2013 Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1. Sirolimus 72-81 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 195-201 23384908-3 2012 The expressions of mTOR, 4E-BP1 and p70S6K at protein and mRNA level in K562 cells with rapamycin treatment were detected by Western blot and RT-PCR. Sirolimus 88-97 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 25-31 22767218-8 2012 Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin. Sirolimus 137-146 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 63-69 22496482-8 2012 However, rapamycin had only a marginal effect on the phosphorylation status of 4E-BP1, another mTORC1 substrate. Sirolimus 9-18 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 79-85 21993902-7 2012 Moreover, treatment of CML cell line (K562) with rapamycin resulted in a decrease of phosphorylation of mTOR, 4E-BP1 and p70S6K. Sirolimus 61-70 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 134-140 22184107-11 2012 4EBP1 phosphorylation, but not that of S6K1, was uniquely resistant to rapamycin in NS5A-Huh7.5 cells, indicative of an alternate phosphorylation mechanism of 4EBP1. Sirolimus 71-80 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 0-5 21240477-7 2011 Remarkably, rapamycin resistance was found to affect specifically the mTORC1/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) branch of the mTORC1 pathway in the presence of 50 mumol/l oleate. Sirolimus 12-21 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 128-134 21922152-12 2012 Importantly, knockdown of LRRK2 associated with high proliferative rate in normal cells and treatment with rapamycin and/or proteosome inhibition suppressed 4E-BP1 protein degradation. Sirolimus 119-128 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 169-175 22071574-0 2011 High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Sirolimus 10-19 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 126-132 22071574-5 2011 We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1). Sirolimus 55-64 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 184-208 22071574-5 2011 We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1). Sirolimus 55-64 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 210-216 22071574-8 2011 In contrast with MDA-MB-231 cells, MCF-7 breast cancer cells survived rapamycin-induced suppression of 4E-BP1 phosphorylation. Sirolimus 70-79 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 103-109 22071574-10 2011 This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E. Sirolimus 48-57 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 156-162 19856312-7 2010 Moreover, rapamycin decreased the phosphorylation of 4E-BP1, the phosphorylation of ERK1/2 and enhanced the phosphorylation of c-Jun NH2-terminal kinase, and the activation of caspase of apoptotic pathways in combination with TXT. Sirolimus 10-19 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 53-59 21177869-8 2011 In addition, depletion of 4E-BP1 expression by RNAi results in an increase of PHLPP expression and resistance to rapamycin-induced down-regulation. Sirolimus 113-122 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 26-32 20980505-5 2011 Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1. Sirolimus 128-137 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 241-247 20728939-3 2010 Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK). Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 99-119 20728939-3 2010 Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK). Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 121-127 19211763-3 2009 However, although the mTOR inhibitor rapamycin suppressed VV-induced inactivation of 4E-BP1, it failed to inhibit eIF4F assembly. Sirolimus 37-46 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 85-91 19773438-7 2009 Suppression of 4EBP1 expression resulted in resensitization of MYC-expressing PrEC to rapamycin and increased autophagy. Sirolimus 86-95 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 15-20 19773438-8 2009 Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy. Sirolimus 82-91 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 124-129 19557637-6 2009 Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1. Sirolimus 8-17 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 272-278 18354181-5 2008 Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 177-183 18644990-3 2008 Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 79-85 18644990-3 2008 Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 104-110 16809313-9 2006 The mTOR kinase inhibitor rapamycin blocked phosphorylation of 4E-BP1 and significantly decreased the level of E7 protein in Caski cells, suggesting that phosphorylation of 4E-BP1 is linked to E7 expression. Sirolimus 26-35 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 63-69 18068336-6 2008 mTOR inhibitor rapamycin and a dominant negative mutant of mTOR suppressed TGFbeta-induced phosphorylation of S6 kinase and 4EBP-1. Sirolimus 15-24 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 124-130 16990847-6 2007 In contrast, full-length 4E-BP1 rapidly becomes rephosphorylated and this process is partially inhibited by rapamycin, PD98059 and CGP74514A. Sirolimus 108-117 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 25-31 16962100-10 2007 Interestingly, acetaldehyde enhanced p70(S6K) activation and depressed 4E-BP1 phosphorylation, the effect of which was blunted and exaggerated, respectively, by rapamycin. Sirolimus 161-170 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 71-77 16717100-9 2006 40 S ribosomal protein S6, a target of p70(S6K), and 4E-BP1, a target of mTOR, were both phosphorylated within 15-25 min of T3 treatment and could be inhibited by wortmannin and rapamycin. Sirolimus 178-187 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 53-59 16809313-9 2006 The mTOR kinase inhibitor rapamycin blocked phosphorylation of 4E-BP1 and significantly decreased the level of E7 protein in Caski cells, suggesting that phosphorylation of 4E-BP1 is linked to E7 expression. Sirolimus 26-35 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 173-179 16282343-3 2006 We show that phosphorylation of mTOR, p70S6K1, and 4E-BP1 was diminished in thrombopoietin-cultured human MKs after rapamycin treatment. Sirolimus 116-125 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 51-57 15763431-10 2005 Stx1 also induced hyperphosphorylation of 4E-BP1 and phosphorylation of S6Kinase; both effects were blocked by rapamycin. Sirolimus 111-120 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 42-48 16489035-7 2006 However, when cap-dependent translation was prevented by transfection with a mutant 4E-BP1 construct, which is resistant to mTOR-induced phosphorylation, cells responded to dexamethasone with enhanced apoptosis, mirroring the effect of coexposure to rapamycin. Sirolimus 250-259 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 84-90 16242075-7 2005 Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E). Sirolimus 39-48 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 148-153 16342424-5 2005 Pretreatment of cells with PD-98059 and rapamycin, inhibitors of mitogen-activated protein kinase (ERK1/2) and mammalian target for rapamycin (mTOR), respectively, partially blocked Ang IV-mediated phosphorylation of 4EBP1. Sirolimus 40-49 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 217-222 15292274-5 2004 Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates. Sirolimus 23-32 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 100-106 15767663-5 2005 Here we show that amino acids regulate the N-terminal phosphorylation sites in 4E-BP1 through the RAIP motif in a rapamycin-insensitive manner. Sirolimus 114-123 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 79-85 15846119-8 2005 Like the mTOR inhibitor rapamycin, the patellazoles inhibit translation through the 4EBP1 and S6 kinase pathways. Sirolimus 24-33 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 84-89 15067056-8 2004 When we examined the phosphorylation of 4EBP-1, a downstream substrate of the mammalian target of rapamycin, we found that rapamycin, but not SFA, inhibited the mammalian target of rapamycin activity. Sirolimus 98-107 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 40-46 15317677-7 2004 Furthermore, ANG II triggered dissociation of the translation initiation factor, eukaryotic initiation factor-4E, from its regulatory binding protein 4E-BP1, which was also inhibited by rapamycin and wortmannin. Sirolimus 186-195 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 150-156 11872747-7 2002 In contrast, IL-6-induced phosphorylation of 4E-BP1 was inhibited by rapamycin, wortmannin, and dominant negative AKT but ERK inhibitors had no effect, indicating ERK function was dispensable. Sirolimus 69-78 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 45-51 12504590-5 2002 Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR. Sirolimus 128-137 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 83-90 14871980-11 2004 Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 75-81 14871980-11 2004 Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin. Sirolimus 85-94 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 75-81 10580837-8 1999 In contrast, wortmannin, a phosphatidylinositol 3-kinase (PI 3"-kinase) inhibitor and the immunosuppressant rapamycin abrogated PHAS-I phosphorylation and caused a reciprocal shift between the fully phosphorylated PHAS-I gamma form and its non-phosphorylated alpha form. Sirolimus 108-117 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 128-134 11231341-7 2001 Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 20-26 11272147-1 2001 Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined. Sirolimus 253-262 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 187-193 11799119-5 2002 The TPA-stimulated phosphorylation of all these sites is sensitive to inhibitors of MEK and to the inhibitor of mTOR, rapamycin, indicating that inputs from both mTOR and MEK are required for the regulation of 4E-BP1 phosphorylation by TPA. Sirolimus 118-127 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 210-216 11410517-6 2001 Using phospho-specific antibody against Thr(70) of 4E-BP1, rapid and persistent dephosphorylation within 30 min of exposure to rapamycin was detected in Rh18 rhabdomyosarcoma cells. Sirolimus 127-136 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 51-57 11023817-5 2000 Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 188-194 11023817-5 2000 Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 239-245 10698949-5 2000 PKCdelta-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive. Sirolimus 72-81 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 37-43 10580837-8 1999 In contrast, wortmannin, a phosphatidylinositol 3-kinase (PI 3"-kinase) inhibitor and the immunosuppressant rapamycin abrogated PHAS-I phosphorylation and caused a reciprocal shift between the fully phosphorylated PHAS-I gamma form and its non-phosphorylated alpha form. Sirolimus 108-117 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 214-220 10200280-7 1999 FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase. Sirolimus 205-214 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 150-156 10200280-2 1999 Depriving cells of amino acids or treating them with the small molecule rapamycin inhibits FRAP and results in rapid dephosphorylation and inactivation of the translational regulators 4E-BP1(eukaryotic initiation factor 4E-binding protein 1) and p70(s6k) (the 70-kDa S6 kinase). Sirolimus 72-81 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 184-240 10200280-5 1999 A calyculin A-sensitive phosphatase is required for the rapamycin- or amino acid deprivation-induced dephosphorylation of p70(s6k), and treatment of Jurkat I cells with rapamycin increases the activity of the protein phosphatase 2A (PP2A) toward 4E-BP1. Sirolimus 56-65 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 246-252 9852118-1 1998 Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway. Sirolimus 122-131 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 228-234 9722592-9 1998 Phosphorylation of p70 S6 kinase and 4E-BP1 is also repressed by PI3K inhibitors as well as by rapamycin, the selective inhibitor of FRAP/mTOR. Sirolimus 95-104 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 37-43 9774438-9 1998 In exploring the signaling pathway responsible for these effects, we find that rapamycin (25 nM) inhibits the ability of branched-chain amino acids to stimulate the phosphorylation of PHAS-I and p70(s6) kinase, suggesting that the mammalian target of rapamycin signaling pathway is involved. Sirolimus 79-88 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 184-190 9334222-1 1997 The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin. Sirolimus 140-149 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 13-23 9715279-7 1998 The signalling inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response. Sirolimus 26-35 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 82-88 9472019-4 1998 PI 3-kinase elicits the phosphorylation of 4E-BP1 in a wortmannin- and rapamycin-sensitive manner, whereas activated Akt-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive. Sirolimus 71-80 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 43-49 9458731-6 1998 Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter. Sirolimus 5-14 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 80-86 9458731-6 1998 Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter. Sirolimus 5-14 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 122-128 9621041-1 1998 Inhibitors of the phosphatidylinositol 3-kinase (PI3 kinase)-FKBP-rapamycin-associated protein (FRAP) pathway, such as rapamycin and wortmannin, induce dephosphorylation and activation of the suppressor of cap-dependent translation, 4E-BP1. Sirolimus 66-75 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 233-239 9334222-3 1997 We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain. Sirolimus 70-79 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 51-61 21528277-0 1997 Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 80-86 21528277-0 1997 Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 88-94 9109413-0 1997 PHAS-I phosphorylation in response to foetal bovine serum (FBS) is regulated by an ERK1/ERK2-independent and rapamycin-sensitive pathway in 3T3-L1 adipocytes. Sirolimus 109-118 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 0-6 9248697-7 1997 Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K. Sirolimus 34-43 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 107-113 9248697-9 1997 Incubating adipocytes with the protein phosphatase inhibitors, calyculin A and okadaic acid, increased PHAS-I phosphorylation and opposed the effects of rapamycin on decreasing PHAS-I phosphorylation. Sirolimus 153-162 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 177-183 9160663-6 1997 Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059. Sirolimus 121-130 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 41-47 9160663-6 1997 Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059. Sirolimus 121-130 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 68-74 9109413-6 1997 However, treatment of cells with a specific p70S6k pathway inhibitor, rapamycin, markedly attenuated FBS-stimulated PHAS-I phosphorylation. Sirolimus 70-79 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 116-122 9109413-7 1997 These results indicate that PHAS-I phosphorylation in response to FBS occurs through an ERK1/ERK2-independent and rapamycin-sensitive pathway in 3T3-L1 adipocytes. Sirolimus 114-123 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 28-34 7629182-7 1995 Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity. Sirolimus 10-19 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 123-129 8633019-2 1996 However, the immunosuppressant rapamycin blocks serum-induced 4E-BP1 phosphorylation and, in parallel, p70s6k activation, with no apparent effect on p42mapk activation. Sirolimus 31-40 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 62-68 8633019-6 1996 The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin. Sirolimus 125-134 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 22-28 8599949-0 1996 Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 40-46 8599949-6 1996 The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation. Sirolimus 4-13 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 81-87 8599949-6 1996 The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation. Sirolimus 4-13 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 184-190 8599949-6 1996 The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation. Sirolimus 128-137 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 81-87 8599949-6 1996 The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation. Sirolimus 128-137 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 184-190 7629182-7 1995 Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity. Sirolimus 10-19 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 50-56 7629182-11 1995 Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 59-65 33773987-7 2021 Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt. Sirolimus 14-23 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 227-232 33549024-8 2021 The levels of key protein p-4EBP1 in the striatum and substantia nigra were both significantly higher in PD group compared with control group (P<0.01), while being pretreated with rapamycin, the expression of p-4EBP1 in the striatum and substantia nigra were both decreased obviously (P<0.01). Sirolimus 180-189 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 28-33 35428493-10 2022 WB results showed that LC3-II/I expression was significantly elevated in KHE primary cells treated with rapamycin, while the level of p-mTOR, p-S6K1, and p-4E-BP1 expression was reduced. Sirolimus 104-113 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 156-162 34738031-1 2021 The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1). Sirolimus 26-35 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 236-297 34738031-1 2021 The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1). Sirolimus 26-35 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 299-304 34421360-9 2021 Mechanistically, rapamycin in combination with trametinib resulted in a greater decrease of phosphorylation of AKT, ERK, mTOR and 4EBP1. Sirolimus 17-26 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 130-135 33865602-11 2021 The expression of p-mTOR, p-4EBP1, and p-P70S6K decreased and the ratio of LC-3 II/LC-3 I elevated after treatment of sirolimus. Sirolimus 118-127 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 28-33 33852892-7 2021 Finally, our findings provide a mechanistic explanation for the differential rapamycin sensitivity of the 4E-BP1 phosphorylation sites. Sirolimus 77-86 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 106-112 35044284-6 2022 Mechanistically, we found elevated phosphorylation of AKT and two downstream effectors of mammalian target of Rapamycin complex 1 (mTORC1), S6 and 4E-Binding Protein 1 (4EBP1) after Rasal2 overexpression in hypoxia-challenged PASMC. Sirolimus 110-119 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 169-174 34874016-9 2022 On the other hand, rapamycin abolished the effects of T-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/ S6K1/4EBP1 signaling pathway in a concentration-dependent manner. Sirolimus 19-28 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 188-193 32108266-4 2020 Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation. Sirolimus 5-14 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 138-144 33189285-11 2021 Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG. Sirolimus 0-9 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 112-117 32753891-13 2020 Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation. Sirolimus 97-106 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 179-184 33660929-2 2021 In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor. Sirolimus 183-192 eukaryotic translation initiation factor 4E binding protein 1 Homo sapiens 130-135